Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers
Abstract
A variety of proton pump inhibitors (PPIs) have been developed in Korea since the introduction of omeprazole (the first PPI) in 1989. PPIs have served as the basic therapeutic approach for the management of gastric acid-related diseases for 30 years and remain among the most widely used drugs. Recently, potassium-competitive acid blockers (PCABs) have been developed both in Korea and abroad, demonstrating superior or non-inferior effects compared to existing PPIs in treating gastroesophageal reflux disease or Helicobacter pylori eradication, among others. Indications vary based on the various types and dosages of PPIs and PCABs, and several factors, including patients' underlying disease, safety profile, particularly with regard to drug-drug interactions, and types of formulations of PPIs and PCABs need to be considered prior to prescribing these medications. In this article, we discuss the criteria for reimbursement of various PPIs and PCABs in Korea, along with considerations for prescribing these drugs based on patients' underlying diseases.
Read the paper
Related studies
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study
- Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.